TapanM.KadiaMD

PubMed

• Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
  Tareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, Lucia Masarova, Keyur Patel, Koichi Takahashi, Prithviraj Bose, John Villarreal, Sherry Pierce, Tapan Kadia, ...> ;American Journal of Hematology. 2024 Apr 13
• Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
  Wei-Ying Jen, Wei Qiao, Farhad Ravandi, Koji Sasaki, Sanam Loghavi, Sa A Wang, Gautam Borthakur, Tapan M Kadia, Ghayas C Issa, Nicholas J Short, Musa Yilmaz, Naval G D...> ;British Journal of Haematology. 2024 Apr 11
• Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
  Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, J...> ;Cancer. 2024 Apr 9
• Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
  Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, N...> ;Haematologica. 2024 Apr 4
• Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
  Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, Naval G Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J Jabbour, Ghayas C Issa, Nav...> ;American Journal of Hematology. 2024 Apr 1
• 1 citations
  Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...
  Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
• Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
  Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Kelly Sharon Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasak...> ;Blood Advances. 2024 Mar 21
• Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
  Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti...> ;The Lancet. Haematology. 2024 Apr 1
• First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
  Rupa Narayan, Ana Alfonso Piérola, William B Donnellan, Antonieta Molero Yordi, Maher Abdul-Hay, Uwe Platzbecker, Marion Subklewe, Tapan Mahendra Kadia, Juan Manuel Al...> ;Clinical and Translational Science. 2024 Mar 1
• Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
  Guillermo Montalban-Bravo, Juan Jose Rodriguez-Sevilla, David Michael Swanson, Rashmi Kanagal-Shamanna, Danielle Hammond, Kelly Chien, Koji Sasaki, Elias Jabbour, Cour...> ;Leukemia. 2024 Feb 28
• Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
  Herling, M., Dearden, C., Zaja, F., El-Sharkawi, D., Ding, W., Bellido, M., Khot, A., Tick, L., Jacobsen, E., Eyre, T., Roos-Weil, D., Kadia, T., Lucchini, E., Pflug, ...> ;Blood Advances. 2024 Feb 27
• Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center pha...
  Issa F Khouri, Kamal Alzahrani, Hagop Kantarjian, Denái R Milton, Alison M Gulbis, Koji Sasaki, Nitin Jain, Nicholas J Short, Tapan Kadia, May Daher, Hind Rafei, Jin S...> ;American Journal of Hematology. 2024 May 1
• BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
  Warren Fiskus, Jessica Piel, Michael P Collins, Murphy Hentemann, Branko Cuglievan, Christopher P Mill, Christine Birdwell, Kaberi Das, John A Davis, Hanxi Hou, Antrix...> ;Blood. 2024 Feb 16
• Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
  Ravandi, F., Pierce, S., Sasaki, K., Kadia, T., DiNardo, C., Yilmaz, M., Short, N., Jabbour, E., Patel, K., Loghavi, S., Borthakur, G., Kantarjian, H.> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 3
• 1 citations
  Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2...
  Bataller, A., Montalban-Bravo, G., Bazinet, A., Alvarado, Y., Chien, K., Venugopal, S., Ishizawa, J., Hammond, D., Swaminathan, M., Sasaki, K., Issa, G., Short, N., Ma...> ;The Lancet. Haematology. 2024 Mar 1
• Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
  Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, Juan Jose Rodriguez-Sevilla, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly S Chien...> ;Clinical Cancer Research. 2024 Apr 1
• Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory-Mutated AML.
  Short, N., Daver, N., Dinardo, C., Kadia, T., Nasr, L., Macaron, W., Yilmaz, M., Borthakur, G., Montalban-Bravo, G., Garcia-Manero, G., Issa, G., Chien, K., Jabbour, E...> ;Journal of Clinical Oncology. 2024 Jan 26
• 1 citations
  Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
  Bataller, A., Bazinet, A., DiNardo, C., Maiti, A., Borthakur, G., Daver, N., Short, N., Jabbour, E., Issa, G., Pemmaraju, N., Yilmaz, M., Montalban-Bravo, G., Takahash...> ;Blood Advances. 2024 Feb 27
• Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
  Birdwell, C., Fiskus, W., Kadia, T., Mill, C., Sasaki, K., Daver, N., DiNardo, C., Pemmaraju, N., Borthakur, G., Davis, J., Das, K., Sharma, S., Horrigan, S., Ruan, X....> ;Leukemia. 2024 Mar 1
• Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
  Jen, W., Rausch, C., Alvarado, Y., McCue, D., Ravandi, F., Sasaki, K., DiNardo, C., Kadia, T., Yilmaz, M., Borthakur, G., Kantarjian, H., McCue, D.> ;Leukemia & Lymphoma. 2024 Mar 1
• Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia ...
  Guillermo Montalban-Bravo, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Farhad Ravandi, Kelly Chien, Naveen Pemmaraju, Danielle Hammond, Xiao Qin Dong, Xuelin Huang, ...> ;British Journal of Haematology. 2024 Mar 1
• 2 citations
  Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
  Fadi G Haddad, Nicholas J Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Yesid Alvarado, Xuemei Wang, Lucia Masarova, Farhad Ravandi, Elias Jabbour, Jeffrey Jorgens...> ;Blood. 2024 Feb 1
• 1 citations
  Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
  Danielle Hammond, Sanam Loghavi, Sa A Wang, Marina Y Konopleva, Tapan M Kadia, Naval G Daver, Maro Ohanian, Ghayas C Issa, Yesid Alvarado, Nicholas J Short, Koji Sasak...> ;Blood Cancer Journal. 2023 Sep 21
• Approach to the Older Patient with Acute Myeloid Leukemia.
  Markie Zimmer, Tapan Kadia> ;Current Oncology Reports. 2023 Nov 1
• 7 citations
  Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
  Alex Bataller, Sanam Loghavi, Yoheved Gerstein, Alexandre Bazinet, Koji Sasaki, Kelly S Chien, Danielle Hammond, Guillermo Montalban-Bravo, Gautam Borthakur, Nicholas ...> ;American Journal of Hematology. 2023 Nov 1
• Join now to see all

Journal Articles

• Response Kinetics and Factors Predicting Survival in Core-Binding Factor Leukemia  
  Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Nature

Abstracts/Posters

• Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Di...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Less Is More 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Diverse Landscape of TET2 Variants in MDS and AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all